ASCC2 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCC3 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCL3 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCL4 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASCL5 Human Pre-designed siRNA Set A contains three designed siRNAs for ASCL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ascorbyl palmitate (Standard) is the analytical standard of Ascorbyl palmitate. This product is intended for research and analytical applications. Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating an vitamin C, it is also used as an antioxidant food additive.

Asebogenin has antimalarial activity in vitro[1]. Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps[2].

Asenapine-13C,d3 is 13C and deuterated labeled Asenapine (HY-10121). Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].

ASF1A Human Pre-designed siRNA Set A contains three designed siRNAs for ASF1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASF1B Human Pre-designed siRNA Set A contains three designed siRNAs for ASF1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASGR1 Human Pre-designed siRNA Set A contains three designed siRNAs for ASGR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASGR2 Human Pre-designed siRNA Set A contains three designed siRNAs for ASGR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASH1L Human Pre-designed siRNA Set A contains three designed siRNAs for ASH1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASH2L Human Pre-designed siRNA Set A contains three designed siRNAs for ASH2L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASIC1 Human Pre-designed siRNA Set A contains three designed siRNAs for ASIC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASIC2 Human Pre-designed siRNA Set A contains three designed siRNAs for ASIC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASIC3 Human Pre-designed siRNA Set A contains three designed siRNAs for ASIC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASIC4 Human Pre-designed siRNA Set A contains three designed siRNAs for ASIC4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASIC5 Human Pre-designed siRNA Set A contains three designed siRNAs for ASIC5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates. Saturated, fused ring, […]

A unique set of molecules containing mild electrophilic moieties that covalently interact with amino acid residues in the target protein. The diversity of our compounds for covalent drug discovery ranges from natural product-like scaffolds to macrocycles, creating multiple opportunities in hit generation for a selected target.

Glycomimetics are designed to mimic the structure of natural carbohydrates and modulate their disease-related functions. Macrocyclic glycomimetics are an extremely interesting class of glycomimetics as they occupy space between small and macro molecules. Macrocyclic glycomimetics are mostly represented by naturally occurring molecules derived from marine microorganisms and bacterial or fungal metabolites.

Macrocycles are promising scaffolds for the design of novel RNA targeting molecules. This collection of macrocycles for RNA consists of very diverse, drug-like molecules which incorporate certain known RNA-recognition elements (e.g. nucleobase ring systems and analogs) distributed within macrocyclic rings or peripheral fragments. As macrocyclic molecules tend to be larger than traditional screening molecules, it […]

ASINEX has elaborated a library of diverse macrocycles using an effective tool box of synthetic methods. The resulting scaffolds are novel, tremendously diverse, medchem-relevant, macrocyclic frameworks. Macrocyles tend to be larger than traditional screening molecules which make them perfect discovery tools for targets with shallow or extended binding sites. At the same time, their unique […]

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and […]

ASIP Human Pre-designed siRNA Set A contains three designed siRNAs for ASIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASL Human Pre-designed siRNA Set A contains three designed siRNAs for ASL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASMT Human Pre-designed siRNA Set A contains three designed siRNAs for ASMT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASMTL Human Pre-designed siRNA Set A contains three designed siRNAs for ASMTL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases[1].

ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases[1].

ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases[1].

ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases[1].

ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases[1].

ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases[1].

ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments[1].

ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments[1].

ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments[1].

ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments[1].

ASN06917370 is a former orphan receptor GPR17 ligand for the study of neurodegenerative diseases. ASN06917370 has an EC50 of 268 pM in [35S]GTPyS experiments[1].

ASNS Human Pre-designed siRNA Set A contains three designed siRNAs for ASNS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ASP6918 is a potent and orally active KRAS G12C inhibitor with an IC50 value of 0.028 µM. ASP6918 inhibits cell growth. ASP6918 shows antitumor activity[1].

ASPA Human Pre-designed siRNA Set A contains three designed siRNAs for ASPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Aspalatone is an orally active antiplatelet aggregant with IC50 of 180 μM. Aspalatone has antioxidant and neuroprotective activities[1][2].

ASPDH Human Pre-designed siRNA Set A contains three designed siRNAs for ASPDH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.